Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Approximately 826,000 children, mostly young infants, die annually from invasive pneumococcal disease. A 6-10-14-week schedule of pneumococcal conjugate vaccine (PCV) is efficacious but neonatal PCV may provide earlier protection and better coverage. We conducted an open randomized controlled trial...

Full description

Bibliographic Details
Main Authors: William S Pomat, Anita H J van den Biggelaar, Suparat Phuanukoonnon, Jacinta Francis, Peter Jacoby, Peter M Siba, Michael P Alpers, John C Reeder, Patrick G Holt, Peter C Richmond, Deborah Lehmann, Neonatal Pneumococcal Conjugate Vaccine Trial Study Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3579820?pdf=render

Internet

http://europepmc.org/articles/PMC3579820?pdf=render

Similar Items